Logo

Jooish

HomeSitesGroupsStatusPodcasts
Sign InSign Up
JBizNews

Israel’s Alpha Tau Reports Tumor Responses in Small Brain Cancer Study

Nov 15, 2026·4 min read

A medical imaging scanner in an examination room. Illustrative archive photograph, not the Alpha DaRT treatment or a REGAIN trial site. Photo: Jo McNamara / Pexels.

Israeli cancer-treatment developer Alpha Tau Medical reported new results Sunday from a small U.S. study of its experimental radiation treatment for recurrent glioblastoma, an aggressive brain cancer that has returned after earlier treatment.

All eight patients treated were alive at the November 11 cutoff, the company said. Six had reached the stage when doctors could assess their tumors by MRI, and all six had shown a response. But the study is still testing whether the procedure can be performed as planned and how safe it is. It is too small, and lacks a comparison group, to establish that the treatment helps patients live longer.

The company’s update describes findings presented by researchers from The Ohio State University Comprehensive Cancer Center at the Society for Neuro-Oncology meeting in Philadelphia. The findings are interim results reported by the company, rather than evidence that the treatment outperforms existing care.

What the tumor scans showed

Alpha Tau said five of the six assessed patients had a complete response, meaning no measurable tumor remained at the treated site under the study’s assessment criteria. The sixth had a partial response, with a 58% decrease in tumor measurements.

The first three patients, whose initial results were reported in May, have now had complete responses confirmed. Responses in the three most recently assessed patients still need confirmation on later scans. A complete response at the treated site does not mean the cancer has been cured.

Among those six assessed patients, the median follow-up from enrollment was 6.9 months, with individual follow-up ranging from 3.1 to 11.6 months. That figure does not describe follow-up for all eight people treated.

One patient developed cancer progression away from the treated area about nine months after treatment and received additional therapy, the company said.

Important uncertainties remain

Follow-up scans showed tissue death, called necrosis, or suspected necrosis in or around the treated area in four of the six assessed patients. Alpha Tau said those findings had caused no symptoms so far.

In two patients, investigators cannot yet tell whether new or increased changes on scans represent necrosis or cancer progression. More imaging and, if needed, a biopsy are being used to investigate. The company cautioned that its reported recurrence findings may change as more information becomes available.

The safety record also includes a previously reported serious event: a grade 3 seizure with temporary paralysis after the seizure, known as Todd’s paralysis. The patient, who had a history of seizures, spent 48 hours in the hospital and recovered with steroid treatment. The company said there were no unanticipated serious adverse events, while disclosing that previously reported seizure.

An early test of an Israeli-developed treatment

Alpha DaRT places radiation sources containing radium-224 directly inside a tumor. The approach is designed to deliver short-range alpha radiation near the cancer while limiting exposure to surrounding healthy tissue. In the brain study, the sources are placed through small holes in the skull using a specialized image-guided delivery system.

Planned sources were successfully placed in all eight patients, according to Alpha Tau. The patients in this update were treated at Ohio State in Columbus.

The REGAIN study is open-label and single-arm: patients and doctors know which treatment is being given, and there is no separate control group. Alpha Tau says it plans to enroll up to 20 patients. Enrollment and follow-up continue.

For the Jerusalem-based developer, the next test is whether the early findings hold up as more patients are treated and followed longer. Alpha DaRT remains investigational for glioblastoma; these results do not establish a survival benefit or an approved new treatment for the disease.

JBizNews Desk | New York

© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.

View original on JBizNews
HomeSitesGroupsStatusPodcastsSign In